Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of CHEK opened at $0.80 on Friday. Check-Cap has a 1 year low of $0.56 and a 1 year high of $3.45. The firm has a fifty day moving average of $1.13 and a 200-day moving average of $1.25. The company has a market cap of $4.69 million, a price-to-earnings ratio of -0.27 and a beta of 0.16.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.